- Home
- SKYE vs FLL Comparison
SKYE vs FLL Comparison
Compare SKYE & FLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- FLL
- Stock Information
- Founded
- SKYE 2012
- FLL 1987
- Country
- SKYE United States
- FLL United States
- Employees
- SKYE N/A
- FLL N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- FLL Hotels/Resorts
- Sector
- SKYE Health Care
- FLL Consumer Discretionary
- Exchange
- SKYE Nasdaq
- FLL Nasdaq
- Market Cap
- SKYE 73.4M
- FLL 116.4M
- IPO Year
- SKYE N/A
- FLL 1993
- Fundamental
- Price
- SKYE $4.17
- FLL $4.09
- Analyst Decision
- SKYE Buy
- FLL Strong Buy
- Analyst Count
- SKYE 6
- FLL 4
- Target Price
- SKYE $16.60
- FLL $6.00
- AVG Volume (30 Days)
- SKYE 2.0M
- FLL 515.3K
- Earning Date
- SKYE 08-08-2025
- FLL 08-05-2025
- Dividend Yield
- SKYE N/A
- FLL N/A
- EPS Growth
- SKYE N/A
- FLL N/A
- EPS
- SKYE N/A
- FLL N/A
- Revenue
- SKYE N/A
- FLL $297,199,000.00
- Revenue This Year
- SKYE N/A
- FLL $9.43
- Revenue Next Year
- SKYE N/A
- FLL $8.18
- P/E Ratio
- SKYE N/A
- FLL N/A
- Revenue Growth
- SKYE N/A
- FLL 13.92
- 52 Week Low
- SKYE $1.14
- FLL $2.86
- 52 Week High
- SKYE $8.26
- FLL $5.90
- Technical
- Relative Strength Index (RSI)
- SKYE 71.01
- FLL 65.35
- Support Level
- SKYE $3.41
- FLL $3.60
- Resistance Level
- SKYE $5.75
- FLL $4.09
- Average True Range (ATR)
- SKYE 0.57
- FLL 0.28
- MACD
- SKYE 0.16
- FLL 0.06
- Stochastic Oscillator
- SKYE 57.41
- FLL 92.37
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About FLL Full House Resorts Inc.
Full House Resorts Inc owns, operates, develops, manages, and invests in casinos and related hospitality and entertainment facilities. It offers facilities related to gaming, hotel, dining, entertainment, retail, and other amenities. The group's reportable segments are Midwest & South, West, and Contracted Sports Wagering, It generates the majority of its revenue from the Midwest & South segment which includes Silver Slipper Casino and Hotel, Rising Star Casino Resort, and American Place. The west segment includes Grand Lodge, Stockman's Casino, Bronco Billy's Casino and Hotel, and Chamonix Casino Hotel. The Contracted Sports Wagering segment comprises on-site and online sports wagering skins.